IP Library Granted Patent US 11,559,515
Granted Patent B2
US 11,559,515 · App. 17/003,552 · Granted Jan 24, 2023

Indole compounds and analogues thereof

Inventors: Pravin L. Kotian (Hoover, AL); Yarlagadda S. Babu (Birmingham, AL); Weihe Zhang (Vestavia Hills, AL); Lakshminarayana Vogeti (Lawrence, KS); Minwan Wu (Vestavia Hills, AL); Venkat R. Chintareddy (Vestavia Hills, AL); Krishnan Raman (Birmingham, AL)
Assignee: BioCryst Pharmaceuticals, Inc.
A61K31/416A61P9/00A61P13/00A61P13/10A61P21/04A61P25/28A61P37/06C07D209/12C07D209/30C07D209/40C07D209/42C07D209/48C07D231/56C07D401/04C07D401/06C07D401/12C07D401/14C07D403/04C07D403/06C07D403/12C07D405/12C07D471/04C07D487/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,559,515
App. No.
17/003,552
Granted
Jan 24, 2023
Kind
B2
Abstract

Disclosed are compounds of formula I, and pharmaceutically acceptable salts thereof. The compounds are inhibitors of the complement system. Also provided are pharmaceutical compositions comprising a compound of formula I, and methods involving use of the compounds and compositions in the treatment and prevention of diseases and conditions characterized by aberrant complement system activity.

Claims (47)

1. A compound represented by Formula (I), or a pharmaceutically acceptable salt thereof:

wherein, independently for each occurrence:

R 1 represents substituted aryl or heteroaryl;

R 2 and R 3 each independently represent H;

R 4 represents H or optionally substituted alkyl, cycloalkyl, (cycloalkyl)alkyl, heterocycloalkyl, (heterocycloalkyl)alkyl, aralkyl, heteroaralkyl, hydroxyalkyl, or haloalkyl;

X represents CH 2 ;

Y is absent or represents CH 2 , CR 15 R 16 , or optionally substituted arylene;

R a represents H;

m is 1;

n is 0 or 1;

R 15 and R 16 are each independently selected from the group consisting of H alkyl, or hydroxyalkyl, wherein alkyl is optionally substituted with one or more substituents selected from the group consisting of —OR 17 and —NR 17 R 18 ;

R 17 and R 18 are each independently selected from the group consisting of H and alkyl

represents

Z 1 represents N;

Z 2 represents CH;

Z 3 represents C;

Z 4 represents CR 8 ;

Z 5 represents CR 5 ;

Z 6 represents CR 6 ;

Z 7 represents CR 9 ;

R 5 and R 6 each independently represent H, halogen, —CN, —NO 2 , —OR 13 , —NR 13 R 14 , —C(O)R 13 , —C(O)OR 13 , —C(O)NR 13 R 14 , NR 13 C(O)R 14 , —NR 13 C(O)OR 14 , —NR 13 C(O)NR 13 R 14 , —NR 13 S(O) p (R 14 ), or optionally substituted alkyl, alkynyl, heteroaryl, aryl, or heterocycloalkyl;

L represents —C(O)R 7 ;

R 7 , independently for each occurrence, represents NH 2 , CH 3 , CF 3 ;

R 8 and R 9 each independently represent H, or —C(O)NR 13 R 14 ;

R 13 and R 14 , independently for each occurrence, represent H or optionally substituted alkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, cycloalkyl, (cycloalkyl)alkyl, heterocycloalkyl, or (heterocycloalkyl)alkyl; or, when R 13 and R 14 are attached to the same atom, R 13 and R 14 taken together with the atom may form an optionally substituted heterocyclic ring; and

p is 0, 1, or 2.

2. The compound of claim 1 , wherein n is 1.

3. The compound of claim 1 , wherein R 1 represents aryl or heteroaryl, substituted by one or more substituents independently selected from the group consisting of halogen, —CN, alkoxy, haloalkoxy, haloalkyl, dialkylamino, heterocycloalkyl, aryl, and heteroaryl; or R 1 represents aryl or heteroaryl, substituted by one or more substituents, at least one of which is halogen.

4. The compound of claim 1 , wherein Y is absent, Y is CH 2 , or Y is CR 15 R 16 .

5. The compound of claim 4 , wherein Y is CR 15 R 16 , and R 15 and R 16 are selected from the group consisting of H, alkyl, or hydroxyalkyl;

wherein alkyl is optionally substituted with OR 17 , —NR 17 R 18 ; and

further wherein R 17 and R 18 are each independently selected from the group consisting of H and alkyl.

6. The compound of claim 1 , wherein R 4 represents H or optionally substituted alkyl, cycloalkyl, (cycloalkyl)alkyl, heterocycloalkyl, aralkyl, hydroxyalkyl, or haloalkyl.

7. The compound of claim 1 , wherein R 4 represents H or optionally substituted alkyl or cycloalkyl.

8. The compound of claim 1 , having the structure of Formula (Ib):

9. The compound of claim 8 , wherein Z 4 and Z 7 each represent CH.

10. The compound of claim 8 , wherein Z 5 represents CR 5 ; and Z 6 represents CR 6 ; and

R 5 and R 6 each independently represent H, halogen, —NR 13 R 14 , —C(O)R 13 , —C(O)OR 13 , —C(O)NHR 14 , —NHC(O)NR 13 R 14 , —NHS(O) 2 (R 14 ), or optionally substituted alkyl, alkynyl, heteroaryl, or aryl.

11. The compound of claim 10 , wherein R 5 and R 6 each independently represent H or alkyl, alkynyl, heteroaryl, or aryl, optionally substituted with one or more substituents selected from the group consisting of aryl, heteroaryl, silyl, alkyl, amino, alkylamino, dialkylamino, —C(O)(alkyl), and halogen.

12. The compound of claim 10 , wherein R 13 and R 14 , independently for each occurrence, represent H or optionally substituted aryl, aralkyl, heteroaryl, heteroaralkyl, cycloalkyl, or (cycloalkyl)alkyl.

13. The compound of claim 1 , wherein R 7 represents NH 2 or CH 3 .

14. The compound of claim 1 , wherein R 7 represents CH 3 .

15. A pharmaceutical composition, comprising a compound of claim 1 ; and a pharmaceutically acceptable carrier.

16. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, selected from the following table:

17. The compound of claim 1 , wherein R 4 represents optionally substituted alkyl, cycloalkyl, or hydroxyalkyl.

18. The compound of claim 1 , wherein Y is CH 2 .

19. The compound of claim 1 , wherein Y is optionally substituted arylene.

Assignments (4)
SECURITY INTEREST Recorded Jan 23, 2026
From: BIOCRYST PHARMACEUTICALS, INC.
To: WILMINGTON TRUST, NATIONAL ASSOCIATION
Reel/Frame 074485/0651 →
RELEASE OF GRANT OF SECURITY INTEREST IN PATENTS Recorded Apr 18, 2023
From: ATHYRIUM OPPORTUNITIES III CO-INVEST 1 LP
To: BIOCRYST PHARMACEUTICALS, INC.
Reel/Frame 063362/0550 →
SECURITY INTEREST Recorded Apr 10, 2023
From: BIOCRYST PHARMACEUTICALS, INC.
To: ATHYRIUM OPPORTUNITIES III CO-INVEST 1 LP
Reel/Frame 063284/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 28, 2020
From: KOTIAN, PRAVIN L.; BABU, YARLAGADDA S.; ZHANG, WEIHE; VOGETI, LAKSHMINARAYANA; WU, MINWAN; CHINTAREDDY, VENKAT R.; RAMAN, KRISHNAN
To: BIOCRYST PHARMACEUTICALS, INC.
Reel/Frame 054198/0907 →